FDA Panel Endorses Bluebird Bio's Beti-cel Gene Therapy For Rare Blood Disease
11/6 07:12
(RTTNews) - An advisory committee to the U.S. Food and Drug Administration voted unanimously to recommend approval of bluebird bio Inc.'s (BLUE) beti-cel gene therapy for people with beta-thalassemia who require regular red blood cell transfusions....